This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Reproduction in whole or in part without permission is prohibited.
Page 1
Seeing the Truth About Childhood Schizophrenia
Elizabeth Montagnese, M.D.
Adult, Child and Adolescent Psychiatrist
Quittie Glen Center for Mental Health in Annville, Pennsylvania
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy
education
Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants
(PharmCon) or the companies that support educational programming. A qualified healthcare professional should always be consulted
before using any therapeutic product discussed. Participants should verify all information and data before treating patients or employing
any therapies described in this educational activity.
This program has been supported by an educational grant from Bristol-Myers Squibb
Legal Disclaimer: The material presented here does not necessarily reflect the views of Pharmaceutical Education Consultants (PharmCon) or
the companies that support educational programming. A qualified healthcare professional should always be consulted before using any
therapeutic product discussed. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
Speaker: Dr. Montagnese is board certified in adult, child, and adolescent psychiatry by the American
Board of Psychiatry and Neurology. Dr. Montagnese provides comprehensive psychiatric evaluation
and treatment for individuals, couples and families. Her primary area of focus is working with children
and adolescents but she also treats adults.Dr. Montagnese received her medical degree at Wayne
State University in Detroit, Michigan. She completed her general psychiatry and child psychiatry
training at the Penn State University Milton S. Hershey Medical Center.Dr. Montagnese is the medical
director at Family and Children Services of Central Pennsylvania. This is a United Way funded
nonprofit agency that serves the greater Harrisburg, York and Lancaster areas. To contact her at this
agency please call 717-238-8118.
Speaker Disclosure: Dr. Montagnese has no actual or potential conflicts of interest in relation to
this program
Seeing the Truth About Childhood Schizophrenia
This program has been supported by an educational grant from Bristol-Myers Squibb
Accreditation:
Pharmacists 798-000-09-075-L01-P
Pharmacy Technicians 798-000-09-075-L01-T
Target Audience: Pharmacists & Technicians
CE Credits:
1.0 Credit hour or 0.1 CEU for
pharmacists/technicians
Expiration Date: 10/20/2011
Program Overview: This program is designed to assist pharmacists review the facets of childhood
schizophrenia, as well as the benefits of managing this disorder with medications. Their knowledge of
available treatment options for children with schizophrenia will be enhanced. The program includes
information on pharmacologic treatments, drug interactions, patient counseling, and a question/ answer
period.
Objectives:
• To state the theories associated with the causes of childhood schizophrenia, as well as detrimental
affects that this disorder may have on its victim’s lives, incorporating information on the prevalence of
this predicament.
• To list therapeutic agents used in the treatment of childhood schizophrenia, and be able to state an
agent’s dosage schedule, mechanism of action, and side effects.
• Review the pharmacist’s role in counseling patients on drug treatment strategies and medication
adherence to improve quality of life and long-term maintenance of childhood schizophrenia patients.
Reproduction in whole or in part without permission is prohibited.
Page 16
References
Diagnostic and Statistical Manual of Mental Disorders, fourth edition, Text Revision, American Psychiatric Association, 2000
Physicians Desk Reference, 2008
Schizophrenia, A Clinician’s Guide, 1995, American Psychiatric Press
Lieberman JA, Stroup TS, McEvoy JP, et al, “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia”, N Engl J Med, 2005;353: 1209-1223
NIMH, Questions and Answers about the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE), http://www.nimh.gov/healthinformation.catieqa.cfm
Wu EQ, Birnbaum HG, et al,“The Economic Burden of Schizophrenia in the United States in 2002”, JClinPsych, 2005, Sept;66(9):1122-1129
Practice Guidelines for the Treatment of Patients with Schizophrenia, Second Edition, 2002, American Psychiatric Association
Practice Parameters for the Assessment and Treatment of Children and Adolescents With Schizophrenia, J.Am.Acad.ChildAdolesc.Psychiatry, 40:7 Supplement, July 2001
Greenstein et al, “Remission Status and Cortical Thickness in Childhood-Onset Schizophrenia,” J.Am.Acad.ChildAdolesc.Psychiatry, 40 (10) 1133-40, Oct. 2008.
Rapport et al, “Autism Spectrum Disorder and Childhood-Onset Schizophrenia: Clinical and Biological Contribution to a Relation Revised,” J. Am.Acad.ChildAdolesc.Psychiatry, 48 (1) 10-18, Jan.2009.